Aggressive Progression in Glioblastoma Cells through Potentiated Activation of Integrin α5β1 by the Tenascin-C-Derived Peptide TNIIIA2.
Animals
Antineoplastic Agents, Alkylating
/ pharmacology
Cell Line, Tumor
Cell Movement
/ drug effects
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Disease Progression
Female
Fibronectins
/ chemistry
Glioblastoma
/ drug therapy
Humans
Integrin alpha5beta1
/ metabolism
Mice, Inbred BALB C
Mice, Nude
Peptides
/ pharmacology
Rats
Temozolomide
/ pharmacology
Tenascin
/ chemistry
Xenograft Model Antitumor Assays
Journal
Molecular cancer therapeutics
ISSN: 1538-8514
Titre abrégé: Mol Cancer Ther
Pays: United States
ID NLM: 101132535
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
03
11
2018
revised:
06
04
2019
accepted:
06
06
2019
pubmed:
14
6
2019
medline:
18
6
2020
entrez:
14
6
2019
Statut:
ppublish
Résumé
Tenascin-C is a member of the matricellular protein family, and its expression level is correlated to poor prognosis in cancer, including glioblastoma, whereas its substantial role in tumor formation and malignant progression remains controversial. We reported previously that peptide TNIIIA2 derived from the cancer-associated alternative splicing domain of tenascin-C molecule has an ability to activate β1-integrin strongly and to maintain it for a long time. Here, we demonstrate that β1-integrin activation by TNIIIA2 causes acquisition of aggressive behavior, dysregulated proliferation, and migration, characteristic of glioblastoma cells. TNIIIA2 hyperstimulated the platelet-derived growth factor-dependent cell survival and proliferation in an anchorage-independent as well as -dependent manner in glioblastoma cells. TNIIIA2 also strongly promoted glioblastoma multiforme cell migration, which was accompanied by an epithelial-mesenchymal transition-like morphologic change on the fibronectin substrate. Notably, acquisition of these aggressive properties by TNIIIA2 in glioblastoma cells was abrogated by peptide FNIII14 that is capable of inducing inactivation in β1-integrin activation. Moreover, FNIII14 significantly inhibited tumor growth in a mouse xenograft glioblastoma model. More importantly, FNIII14 sensitized glioblastoma cells to temozolomide via downregulation of O
Identifiants
pubmed: 31189613
pii: 1535-7163.MCT-18-1251
doi: 10.1158/1535-7163.MCT-18-1251
doi:
Substances chimiques
Antineoplastic Agents, Alkylating
0
Fibronectins
0
Integrin alpha5beta1
0
Peptides
0
Tenascin
0
Temozolomide
YF1K15M17Y
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1649-1658Informations de copyright
©2019 American Association for Cancer Research.